Efficacy and safty results from a phase III trail of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067). ASCO Annual Meeting, LBA 1, ASCO Daily News, Sunday May 31 2015, D12 - Wolchok, J. D